The analysis included adults aged 19 years or older and examined three mental health indicators. Elevated depressive symptoms were defined as a score of at least 10 on the Patient Health Questionnaire-9, or PHQ-9, while elevated anxiety symptoms were defined as a score of at least 10 on the seven-item Generalized Anxiety Disorder-7, or GAD-7. Suicidal ideation referred to whether a participant had experienced thoughts of suicide during the previous 12 months. The study therefore focused on the associations between dietary intake categories and the measured indicators, rather than demonstrating any effect of changing diet or nutrient intake on mental health.

Dietary exposure was assessed with a single 24-hour dietary recall. Separately surveyed supplement quantities were not added to the estimates, meaning the exposure analysis concerned food-derived nutrient intake rather than total intake including supplements. High magnesium intake was defined as at least 350 mg per day for men and at least 250 mg per day for women. High omega-3 intake was defined as at least 1.5 g per day. Because the study used one day of dietary reporting, the researchers cautioned that a single recall may not accurately represent usual intake.

The investigators used survey-weighted logistic regression to account for the complex design of the national examination, incorporating survey strata, clusters and integrated health and nutrition weights. The models included 13 covariates. For high omega-3 intake, the adjusted odds ratio for elevated depressive symptoms was 0.833, with a 95% confidence interval of 0.556–1.249 and p = 0.375. The corresponding adjusted odds ratios were 0.929 for elevated anxiety symptoms, with a 95% confidence interval of 0.631–1.367 and p = 0.705, and 0.822 for suicidal ideation, with a 95% confidence interval of 0.557–1.215 and p = 0.324. All 12 primary adjusted tests—including analyses of magnesium intake, joint intake and the interaction between magnesium and omega-3 intake—had p values greater than 0.05. These confidence intervals were wide, indicating imprecision in the estimated associations.

An exploratory analysis also assessed symptom-score trends across quartiles of nutrient intake. The omega-3–PHQ-9 trend had a nominal p value of 0.026, but its approximate Benjamini–Hochberg-adjusted p value was 0.104 across four trend tests. Thus, the exploratory finding was not statistically significant after the multiple-testing adjustment. The cross-sectional design cannot establish whether dietary intake preceded the mental health indicators or whether mental health was related to eating habits, while the one-day dietary assessment further limits conclusions about usual nutrient exposure. The results do not show that magnesium or omega-3 intake improves mental health, and they do not establish that such intake has no relationship with mental health. Prospective studies with repeated dietary measurements could help clarify the direction and magnitude of these associations.

Subject of Research: Dietary magnesium and omega-3 intake in relation to mental health indicators among Korean adults

Article Title: Associations of dietary magnesium and omega-3 fatty acid intake with mental health indicators among Korean adults: a population-based cross-sectional study

Article References: Lee, H., & Choi, M. (2026). Associations of dietary magnesium and omega-3 fatty acid intake with mental health indicators among Korean adults: a population-based cross-sectional study. BMC Public Health. https://doi.org/10.1186/s12889-026-29827-3

Image Credits: AI Generated

DOI: 10.1186/s12889-026-29827-3

Keywords: dietary magnesium, omega-3 fatty acids, depressive symptoms, anxiety symptoms, suicidal ideation, mental health, dietary intake, Korean adults, cross-sectional study, Associations, dietary, magnesium

The research team started from a well-known industrial workhorse, the Cu-Cr-Zr alloy, whose strength comes from nanoscale chromium-rich precipitates that form during aging treatment. These precipitates block dislocations, the line defects that carry plastic deformation, and thereby raise the alloy’s resistance to bending and stretching. The problem is that traditional strengthening methods, whether adding more solute atoms or increasing dislocation density through heavy deformation, tend to reach a ceiling where further gains in strength come only at unacceptable losses in conductivity. To push past this ceiling, the researchers introduced small amounts of zinc and magnesium into the Cu-Cr-Zr base, then subjected the material to a sequence of solution treatment, rolling at cryogenic temperature, and peak aging.

The resulting Cu-Cr-Zn-Zr-Mg alloy achieved a hardness of 226.6 HV and an ultimate tensile strength of 623.92 MPa, improvements of 9.2 HV and 22.62 MPa respectively over the comparable Cu-Cr-Zr alloy processed the same way. More remarkably, the alloy retained an electrical conductivity of 79.53 percent IACS, the international annealed copper standard that serves as the benchmark for conductor performance. That combination, strength above 620 MPa together with conductivity near 80 percent of pure copper, places the material in a regime that conventional strengthening approaches struggle to reach, and it does so with only trace quantities of the added elements rather than the substantial alloying loads that would normally be required.

The key to understanding how zinc and magnesium accomplish this lies in a quantum-mechanical property called the generalized stacking fault energy, or GSFE. The stacking fault energy describes the energetic cost of creating a fault in the regular stacking of atomic planes in the face-centered cubic crystal structure of copper. When this energy is lowered, it becomes easier for deformation twins, mirror-symmetric regions of the crystal, to nucleate and grow during plastic deformation. The study found that the addition of zinc and magnesium effectively reduces the GSFE of the alloy, which facilitates the formation of high-density dislocations and promotes the refinement of nanotwins, twin lamellae only a few nanometers thick that pack an enormous amount of interface area into the microstructure.

This connection between solute chemistry and defect structure has deep roots in the literature on copper alloys. Previous work on Cu-Al systems showed systematically that lowering the stacking fault energy changes the character of deformation twins, producing thinner twin lamellae and higher twin densities, and the same principle applies here. Nanotwins are particularly valuable in a high-conductivity alloy because twin boundaries are coherent, meaning the atoms across the boundary remain in registry, so they scatter dislocations efficiently while offering comparatively little resistance to electron flow. By using zinc and magnesium to tip the energetics toward twin formation, the researchers essentially recruited a strengthening mechanism that is unusually kind to conductivity.

The trace elements also reshape the precipitation behavior that governs the aging response. Chromium in copper exists in two crystal structures, the face-centered cubic form that dissolves in the matrix at high temperature and the body-centered cubic form that appears as the equilibrium precipitate. The study found that zinc and magnesium improve the uniformity and dispersion of the nano-precipitates that form during aging, spreading them more evenly through the matrix where they can block dislocations most effectively. At the same time, these elements delay the transformation of fcc chromium to bcc chromium, slowing the coarsening pathway that would otherwise allow precipitates to grow large and lose their strengthening power. Finer, more numerous, and more uniformly distributed precipitates mean more barriers per unit volume, and barriers of nanometer scale are precisely the size that strengthens without substantially impeding conduction.

Cryogenic rolling adds a second dimension to the microstructural engineering. Deforming the alloy at cryogenic temperatures, where dynamic recovery is suppressed, allows dislocations to accumulate to densities that would be impossible at room temperature, and it promotes grain refinement into the ultrafine and nanometer regime. The resulting microstructure is not uniform, however. Fine grains formed during rolling coexist with coarser grains, creating a heterogeneous structure in which different regions deform by different amounts under load. When the alloy is stretched, the soft coarse grains yield first while the hard fine grains resist, and the mismatch generates internal stresses that strengthen the material, a phenomenon known as heterogeneous deformation induced, or HDI, strengthening. This mechanism, extensively described in the work of Yuntian Zhu and colleagues on back stress and hetero-deformation, allows strength and ductility to improve together rather than trading off.

The combination of mechanisms is what makes the result noteworthy. Solid solution strengthening from the trace solutes, dislocation strengthening from the cryogenic deformation, twin boundary strengthening from the refined nanotwins, precipitation strengthening from the uniformly dispersed nano-precipitates, and HDI strengthening from the bimodal grain structure all contribute simultaneously, while the coherent twin boundaries and well-dispersed precipitates preserve the electron pathways that carry the alloy’s conductivity. The microstructural modifications induced by the zinc and magnesium additions, spanning grains, twins, dislocations, and precipitates, enhance the strength of the Cu-Cr-Zn-Zr-Mg alloy while maintaining high electrical conductivity, the authors conclude.

The implications reach across several demanding industries. Cu-Cr-Zr family alloys serve as electrode materials for resistance welding, where they must conduct current and resist wear at elevated temperature; as conductor and structural components in high-speed rail and electric vehicles; and as candidate heat-sink materials in fusion reactor first walls, where thermal and mechanical demands are extreme. Any alloy that raises the strength ceiling without sacrificing conductivity extends the operating envelope of these systems, whether by allowing higher welding currents, more compact motor windings, or longer service life under thermal cycling. Because the approach relies on trace additions and standard thermomechanical processing, solution treatment, cryogenic rolling, and aging, it is compatible with existing production routes rather than requiring exotic manufacturing.

The work also contributes to a broader scientific campaign that has accelerated in recent years, the deliberate use of heterogeneous microstructures to break the property trade-offs that homogeneous materials obey. Studies of fractal structures, lamellar grain-boundary heterostructures, and multi-stage deformation in CuCrZr alloys have shown that strength, ductility, and conductivity can rise together when the microstructure is designed across multiple length scales. The Guizhou team’s demonstration that two inexpensive trace elements can orchestrate this design, lowering stacking fault energy to refine twins while stabilizing precipitates and building a bimodal grain structure, offers a recipe that other alloy designers can adapt. As electrification accelerates worldwide and the demand for conductors that are also strong continues to grow, strategies of this kind, published in the Journal of Materials Science with the DOI 10.1007/s10853-026-13953-9, point toward a future in which the metals that carry our current no longer have to choose between strength and conduction.

Subject of Research: Materials Science

Article Title: Effect of microstructural evolution on properties of Cu–Cr–Zr (Zn, Mg) alloys during cryogenic rolling and aging process

Article References: Liu, R., Ou, M., & Liang, Y. (2026). Effect of microstructural evolution on properties of Cu–Cr–Zr (Zn, Mg) alloys during cryogenic rolling and aging process. Journal of Materials Science. https://doi.org/10.1007/s10853-026-13953-9

Image Credits: AI Generated

DOI: 10.1007/s10853-026-13953-9

Keywords: copper alloys, Cu-Cr-Zr, cryogenic rolling, aging treatment, stacking fault energy, nanotwins, precipitation strengthening, HDI strengthening, electrical conductivity, zinc, magnesium, materials science

The review, published in the journal Nutrition Research Reviews, is a narrative assessment of existing evidence rather than a single clinical trial. Its authors conclude that pistachios represent a promising whole food for sleep research and map out how the nut’s nutrient profile may influence processes related to sleep quality, falling asleep, staying asleep and regulation of the sleep-wake cycle. Rather than claiming that pistachios are proven to improve sleep, the paper builds a biological rationale for why the nut deserves systematic study, and it lays out the randomized controlled trials that researchers say must come next before any health claims can be made.

The core of the argument rests on chemistry. Pistachios provide tryptophan, an essential amino acid the body uses to manufacture serotonin, a brain chemical involved in sleep regulation, and melatonin, the hormone that helps govern the sleep-wake cycle. A one-ounce serving of pistachios delivers about 71 milligrams of tryptophan, roughly 20 percent of the daily amount recommended for a 70-kilogram, or 154-pound, adult, based on an intake guideline of 5 milligrams per kilogram of body weight. Crucially, pistachios also supply vitamin B6 and magnesium, cofactors that help the body convert tryptophan along the metabolic pathway toward serotonin and melatonin, meaning the nut contains both the raw material and some of the enzymatic machinery associated with its processing.

Melatonin itself is a second thread in the review. In addition to supporting the body’s own synthesis of the hormone through the tryptophan pathway, pistachios contain phytomelatonin, the form of melatonin produced by plants. The review notes, however, that the absorption and effects of phytomelatonin from eating pistachios have not been established in people, a key caveat that separates the current evidence from any practical recommendation. Laboratory work described in the review suggests that the food matrix of the nut, the natural structure in which its nutrients and plant compounds are packaged and interact, may contribute to a longer release of phytomelatonin during digestion, but whether that translates into measurable changes in circulating melatonin remains an open question for human studies.

Beyond the melatonin pathway, the review highlights a neurological angle. Vitamin B6 and magnesium are involved in the production and function of gamma-aminobutyric acid, or GABA, the brain’s principal inhibitory neurotransmitter. GABA helps quiet nerve activity and plays a well-documented role in regulating sleep, which is why compounds that enhance GABAergic signaling are frequent targets of hypnotic drugs. The idea that ordinary dietary components could support the same calming signaling system, without pharmacological intervention, is one reason clinicians and sleep researchers find the pistachio profile intriguing.

A third proposed mechanism runs through the gut. Pistachios provide fiber and polyphenols that gut microbes can ferment and transform into other compounds, some of which may influence communication between the gut and the brain, including signaling involved in sleep regulation. As part of the review, researchers assessed laboratory studies that simulated digestion and fermentation of pistachios to explore how the food matrix may affect when and how the nut’s components become available to the body. Those findings showed that gut microbes can ferment pistachio fiber, transform its polyphenols and contribute to a longer release of phytomelatonin, supporting the plausibility of a gut-brain axis route by which the nut might affect sleep physiology.

What distinguishes this review from much of the existing nutrition-and-sleep literature is its emphasis on the whole food. Most research to date has examined individual nutrients, extracts or supplements in isolation. Pistachios bring several sleep-related components together naturally in a single food, creating an opportunity to study how they may act in combination. This packaged structure is known as the food matrix, and the review argues that nutrients may behave differently when consumed as part of it than they do when taken as isolated compounds. Studying whole pistachios, the authors contend, is therefore the scientifically appropriate next step.

That perspective comes through clearly from the review’s senior and corresponding author, Marie-Pierre St-Onge, PhD, director of the Center of Excellence for Sleep and Circadian Research at Columbia University Irving Medical Center. “Pistachios are compelling for sleep research because they bring together several nutrients and plant compounds connected to sleep physiology within one whole food,” she said. “Rather than focusing on a single ‘sleep nutrient,’ this review provides a rationale for studying how the complete pistachio food matrix may affect sleep-related pathways.” Her framing underscores that the paper is a call for research design, not a dietary prescription.

The path forward the authors describe is specific. They call for randomized controlled trials examining whole-pistachio consumption, dose-response relationships, melatonin levels, sleep outcomes and the bioavailability of key compounds. They also recommend investigating whether pistachio variety, growing conditions and processing influence the nutrient and bioactive content of the nuts, variables that could matter enormously if the food matrix is indeed the active factor. “Well-designed human trials can help us determine whether the unique combination of nutrients and bioactive compounds in the pistachio food matrix produces measurable changes in melatonin, sleep quality, sleep duration or other sleep outcomes,” St-Onge explained. That next phase is already underway: several university-led human clinical studies examining pistachios and sleep are in progress with support from American Pistachio Growers, although results are not yet available.

For now, the honest summary is that pistachios are a scientifically promising, biologically plausible candidate for sleep research, but not a demonstrated sleep aid. The review was funded in part by American Pistachio Growers and the National Institutes of Health, and the funding relationship is disclosed in the paper’s conflict of interest statement. Consumers hoping a bedtime handful of nuts will transform their sleep should temper expectations until trial data arrive. Yet the broader takeaway may be the most interesting part: the review makes a case that how nutrients are packaged inside whole foods could be as important as the nutrients themselves, and that this packaging, the food matrix, deserves the same scientific scrutiny that single compounds have long received. If future trials confirm the mechanisms mapped here, the lowly pistachio could become a model for how food-based interventions approach one of public health’s most stubborn problems.

Subject of Research: The role of pistachio nutrients and bioactive compounds in sleep health

Article Title: Can pistachios support sleep? Here’s what a new scientific review found

Article References: Can pistachios support sleep? Here’s what a new scientific review found. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: pistachios, sleep, melatonin, tryptophan, nutrition research, food matrix, gut-brain axis, vitamin B6, magnesium, phytomelatonin, GABA, polyphenols

The study, conducted by Susanne Mitschke of Harvard T.H. Chan School of Public Health, recruited 226 perimenopausal or postmenopausal participants aged 45 to 65 through online health forums, social media platforms, menopause support groups, and email newsletters between July 21 and August 12, 2024. All participants reported experiencing menopausal or perimenopausal symptoms, and women with a history of breast cancer, heart disease, or blood clots were excluded because those conditions are established contraindications to hormone therapy. The survey, administered through the Qualtrics platform, took a median of 2.8 minutes to complete and captured sociodemographic characteristics, supplement use, perceived effectiveness, information sources, and perceptions of menopausal hormone therapy, commonly abbreviated MHT.

The headline numbers reveal a striking gap between general supplement consumption and symptom-targeted use. Current use of at least one dietary supplement for any purpose was reported by 138 participants, or 61.1 percent of the sample, with a 95 percent confidence interval of 54.6 to 67.2 percent. But when asked directly whether they were using supplements to manage menopause symptoms, only 65 participants, or 28.9 percent, answered yes. Of the 138 current supplement users, 72 answered no to the menopause-specific question, indicating that their supplement use was driven by motivations other than symptom relief. The two survey items, the study notes, measure different constructs and should not be read as bounds on a single quantity.

The product profile among users further underscores this distinction. Multivitamins led the list at 55.8 percent of supplement users, followed by vitamin D at 52.9 percent, magnesium at 51.4 percent, and probiotics at 41.3 percent. By contrast, botanical products with a more menopause-specific evidence base, such as black cohosh, soy isoflavones, red clover, and evening primrose oil, were reported far less frequently. Black cohosh, for instance, was used by just 10.1 percent of supplement users, while soy isoflavones and St. John’s Wort each registered at 1.4 percent. Notably, participants who reported menopause-targeted use were significantly more likely to take black cohosh, any herbal or botanical product, and probiotics, whereas general users more often reported multivitamins and calcium, products typically associated with overall health maintenance or bone support.

Usage patterns among supplement users were remarkably consistent. Of the 110 users who answered the duration question, 53.6 percent had been taking supplements for more than a year, and of the 125 who answered the frequency question, 88.8 percent reported daily use. Users reported a median of three supplement types. Yet perceived effectiveness was decidedly mixed: among the 115 users who rated their supplements, 47.0 percent described them as somewhat or very effective, 27.8 percent were neutral, and 25.2 percent rated them as somewhat or very ineffective. Perceived effectiveness was significantly higher among those using supplements specifically for menopause symptoms, at 56.2 percent, compared with 35.3 percent among general users, a difference the study suggests may simply reflect that the latter group was not seeking symptom relief in the first place.

On the hormone therapy front, awareness was high but enthusiasm tempered by lingering fears. Some 82.7 percent of participants were aware of MHT, and 11.5 percent were currently using it. Perceptions leaned neutral or positive, with 45.1 percent neutral and 36.7 percent somewhat or very positive. However, concerns about specific risks were widespread: 47.8 percent cited increased breast cancer risk, 44.7 percent cited blood clotting, 40.7 percent cited stroke, and 37.2 percent cited heart disease. Only 36.3 percent reported no concerns at all. These figures echo the enduring influence of the initial Women’s Health Initiative findings, even though subsequent analyses have nuanced the original results, suggesting that for women younger than 60 or within 10 years of menopause onset without contraindications, the benefits of MHT often outweigh the risks.

The study also uncovered significant demographic disparities in MHT awareness. Awareness rose monotonically with income, reaching 100 percent among participants earning $200,000 or more, compared with 66.2 percent among those earning less than $50,000. Awareness was lowest among participants identifying as Black or African American, at 38.5 percent, those with a high school diploma or GED, at 69.2 percent, and current smokers, at 67.6 percent. Current MHT use was associated with income alone, ranging from 4.2 percent among the lowest earners to 33.3 percent among the highest. Because several racial and ethnic groups were represented by very few participants, the authors caution that these comparisons rest on small numbers and call for larger, more diverse studies to confirm the patterns.

In the multivariable logistic regression, smoking status emerged as the only participant characteristic significantly associated with any supplement use. Former smokers had 2.98 times the odds of supplement use compared with current smokers, and never smokers had 3.92 times the odds, with the overall smoking effect reaching statistical significance at p equals 0.012. Participants aged 61 to 65 also showed higher odds, though that estimate was based on just 17 users and 2 non-users and carried a correspondingly wide confidence interval. Critically, when the analysis was repeated with menopause-targeted use as the outcome, none of the covariates was associated with the result, suggesting the smoking association reflects general wellness-oriented behavior rather than menopause-specific self-treatment. The overall model explained little of the variation in supplement use, with a McFadden pseudo-R-squared of just 0.075.

Information-seeking patterns revealed a clear hierarchy of trust. Healthcare providers were the most commonly cited source of information about menopause symptom management, at 69.0 percent of all participants, closely followed by the internet, online articles, blogs, and websites at 67.7 percent. When asked to rate trustworthiness on a scale, 75.3 percent of those rating healthcare providers judged them trustworthy or extremely trustworthy. Social media influencers, by contrast, were rated extremely untrustworthy by 47.1 percent of the 206 respondents who evaluated that source, making them the least trusted information channel by a wide margin. Among supplement users themselves, personal research was the leading factor influencing product choice at 42.5 percent, followed by recommendations from healthcare providers at 29.2 percent, while social media influencers and marketing each influenced just 0.9 percent of users.

The authors are careful to frame the findings within the study’s limitations. The voluntary response sampling means the prevalence estimates describe a self-selected sample of women with a particular interest in menopause and wellness, not the broader population of midlife women. The sample was also predominantly white, at nearly 80 percent, and highly educated, with 87.6 percent holding credentials above a high school diploma. The questionnaire was developed for the study and not formally validated, and it did not measure symptom severity with a validated instrument or distinguish perimenopausal from postmenopausal participants. Because the supplement list item did not ask the purpose of each product, the study cannot establish which specific supplements were taken exclusively for menopause symptoms. Despite these constraints, the findings highlight a clear clinical imperative: healthcare providers, who remain the most trusted source of information, have a significant opportunity to proactively ask about supplement use, provide balanced counseling on both evidence-based hormone therapy and the heterogeneous evidence behind popular supplements, and help women make informed, individualized decisions about managing this consequential life transition.

Subject of Research: Dietary supplement use and perceptions of menopausal hormone therapy among symptomatic menopausal women aged 45 to 65

Article Title: Dietary supplements are commonly used for menopause symptoms amid concerns about hormone therapy: a cross-sectional study

Article References: Mitschke, S. (2026). Dietary supplements are commonly used for menopause symptoms amid concerns about hormone therapy: a cross-sectional study. Frontiers in Global Women's Health, 7, Article 1924461. https://doi.org/10.3389/fgwh.2026.1924461

Image Credits: AI Generated

DOI: 10.3389/fgwh.2026.1924461

Keywords: menopause, dietary supplements, menopausal hormone therapy, women's health, black cohosh, vitamin D, magnesium, probiotics, Women's Health Initiative, cross-sectional study, health information sources, perimenopause

Gestational diabetes mellitus is a form of glucose intolerance that first appears during pregnancy and typically resolves after delivery, but its consequences can be far from temporary. Poorly controlled maternal blood sugar raises the risk of macrosomia, in which the baby is born excessively large, and increases the likelihood of birth injuries, cesarean delivery, and neonatal metabolic problems. Over the longer term, women who develop GDM face elevated lifetime risks of type 2 diabetes and cardiovascular disease, while their children carry a higher susceptibility to obesity and metabolic dysfunction. Because the condition is so prevalent, researchers have long sought modifiable risk factors that could be identified and corrected before the disease takes hold.

Known susceptibility factors include maternal age, pre-pregnancy body mass index, and a family history of diabetes, but the role of mineral metabolism has received comparatively little systematic attention. The research team, led by Achou Su, Jie Zhang, and colleagues at the Fourth Hospital of Shijiazhuang, focused on three minerals with well-established biochemical roles in glucose handling. Magnesium acts as a cofactor in enzymes of energy metabolism and protein synthesis and has been shown in previous trials to improve insulin sensitivity when supplemented. Calcium participates in insulin signaling within pancreatic beta cells and in calcium-dependent transport proteins whose disruption has been observed in GDM. Phosphorus, by contrast, has a more ambiguous metabolic reputation: dietary phosphorus intake has been linked in a U-shaped pattern to new-onset diabetes in the general Chinese population, yet its relationship to GDM had remained unreported.

The study population consisted of 700 women aged 18 to 45 who received antenatal care and delivered at the hospital between January 2022 and December 2023. All participants carried singleton pregnancies and had no pre-existing metabolic diseases, thyroid disorders, liver or kidney disease, immune conditions, or polycystic ovary syndrome. Women with a history of abnormal glucose tolerance or diabetes before pregnancy were excluded, as were those with abortion or bleeding during delivery. Blood samples were drawn in the morning after at least eight hours of fasting, at 24 to 28 weeks of gestation, and analyzed on a Roche Cobas 701 automated biochemical analyzer using manufacturer-specific calibrators. Crucially, the mineral measurements and the oral glucose tolerance test used to screen for GDM were performed at the same visit, before any dietary adjustment or hypoglycemic therapy had begun.

The diagnostic framework followed international and national standards. GDM was diagnosed when at least one of three glucose thresholds was met during the oral glucose tolerance test: a fasting plasma glucose between 5.1 and 6.9 mmol/L, a one-hour value of 10 mmol/L or higher, or a two-hour value between 8.5 and 11 mmol/L. Anemia was graded by hemoglobin concentration, with mild anemia defined as 100 to below 110 g/L, moderate as 70 to below 100 g/L, and severe as below 70 g/L. Preterm birth was defined as delivery before 37 weeks of gestation. Additional outcomes, including premature rupture of membranes, chorioamnionitis, preeclampsia, macrosomia, low birth weight, and neonatal respiratory distress syndrome, were classified according to ACOG and WHO criteria.

Of the 700 women, 571 experienced at least one adverse pregnancy outcome, while 129 had no gestational complications or abnormal delivery outcomes. Baseline characteristics—including age, pre-pregnancy BMI, education, household income, parity, family history of diabetes, and prior adverse pregnancy history—were statistically indistinguishable between the two groups, which strengthened the case that any differences in mineral levels were not simply reflections of demographic imbalance. When the researchers compared serum mineral concentrations between women who developed GDM and those who did not, all three minerals showed significant differences, with the GDM group exhibiting lower magnesium and calcium and higher phosphorus.

To quantify these associations, the team converted mineral values into increments of 0.1 mmol/L and applied multivariable logistic regression, adjusting for age, preconceptional BMI, family history of diabetes, adverse pregnancy history, and parity. Each 0.1 mmol/L increase in serum magnesium was associated with an 28 percent reduction in GDM odds (adjusted odds ratio 0.718, 95% CI 0.576–0.896, p = 0.003), while the same increment in calcium was linked to a 52 percent reduction (OR 0.484, 95% CI 0.400–0.585, p < 0.001). Phosphorus moved in the opposite direction: each 0.1 mmol/L rise in serum phosphorus increased the odds of GDM by roughly 15 percent (OR 1.145, 95% CI 1.016–1.290, p = 0.027). Calcium also showed a protective association with anemia (OR 0.729, 95% CI 0.618–0.860, p < 0.001) and with preterm birth (OR 0.687, 95% CI 0.501–0.927, p = 0.014), whereas phosphorus was positively associated with preterm birth risk (OR 1.403, 95% CI 1.118–1.762, p = 0.004).

Receiver operating characteristic (ROC) analysis added a predictive dimension to the findings. Among the three minerals individually, calcium showed the strongest discriminative ability for GDM, with an area under the curve (AUC) of 0.684 (95% CI 0.639–0.730, p < 0.001); at a cut-off of 2.025 mmol/L it achieved a sensitivity of 65.4 percent and a specificity of 68.9 percent. Magnesium yielded an AUC of 0.588, with a cut-off of 0.725 mmol/L giving 64.9 percent sensitivity and 52.9 percent specificity, while phosphorus was the weakest single predictor at an AUC of 0.559. When the three minerals were combined into a single logistic regression model, the AUC rose to 0.733 (95% CI 0.691–0.775, p < 0.001), with an optimal probability cut-off of 0.301 delivering 66.8 percent sensitivity and 72.9 percent specificity. The combined model, the authors note, provides superior clinical risk stratification compared with any single mineral measurement.

The biological mechanisms underlying these associations are plausible but not yet proven. Magnesium and calcium are thought to reduce insulin resistance and promote insulin sensitivity, thereby supporting stable glycemic control. Prior research has shown that magnesium supplementation during pregnancy can lower fasting blood glucose in women with GDM and upregulate the gene expression of glucose transporter 1, improving glucose and lipid metabolism. Combined calcium and vitamin D supplementation has likewise been shown to reduce fasting glucose and serum insulin in GDM patients. On the other side of the ledger, elevated phosphate may disrupt glucose homeostasis through the FGF-23/Klotho signaling pathway, a hormonal axis that regulates phosphate and vitamin D balance, and excess phosphorus has been shown to promote reactive oxygen species production, driving pancreatic beta-cell apoptosis and reduced insulin secretion. High phosphorus may also activate the NLRP3 inflammasome, a molecular complex implicated in the initiation of labor, which could explain the observed link to preterm birth.

The authors are careful to frame their conclusions as observational correlations rather than causal claims. The retrospective design carries inherent limitations: standardized records of antenatal mineral, vitamin D, and combined nutritional supplements were not systematically archived, potentially introducing confounding bias; only total serum calcium was measured without albumin correction, so physiological gestational hypoalbuminemia may have lowered total calcium readings independent of biologically active ionized calcium; mineral levels were tested only once, at 24 to 28 weeks, and therefore cannot capture the dynamic changes of mineral metabolism across the full course of pregnancy; and, as an observational study, the work cannot establish definitive causal relationships, although the simultaneous timing of blood collection and GDM screening reduced the risk of reverse causation. The team explicitly states that randomized controlled trials are essential before any supplementation recommendations can be drawn, and that larger prospective studies are needed to verify the findings. Still, the results point toward a practical possibility: that a modest panel of mineral measurements, already part of routine prenatal bloodwork in many settings, could help clinicians identify women at elevated risk of gestational diabetes earlier in pregnancy and tailor nutritional guidance accordingly.

Subject of Research: Association of second-trimester serum magnesium, phosphorus, and calcium levels with gestational diabetes mellitus and adverse pregnancy outcomes

Article Title: The correlation between serum magnesium, phosphorus, and calcium levels during pregnancy and the risk of gestational diabetes mellitus as well as adverse pregnancy outcomes

Article References: Su, A., Zhang, J., Fan, X., Song, W., Li, M., Yu, T., & Zhang, J. (2026). The correlation between serum magnesium, phosphorus, and calcium levels during pregnancy and the risk of gestational diabetes mellitus as well as adverse pregnancy outcomes. Frontiers in Clinical Diabetes and Healthcare, 7, Article 1939424. https://doi.org/10.3389/fcdhc.2026.1939424

Image Credits: AI Generated

DOI: 10.3389/fcdhc.2026.1939424

Keywords: gestational diabetes mellitus, magnesium, phosphorus, calcium, pregnancy outcomes, preterm birth, anemia, mineral metabolism, insulin resistance, retrospective cohort study, maternal nutrition, ROC analysis

The research team, led by B. Sułkowski together with P. Pałka, G. Boczkal, M. Mroczkowski, and A. Kula, processed three materials: high-purity zinc with a purity of 99.95 percent, and two zinc–magnesium alloys containing 0.5 and 1 weight percent magnesium. Rather than heating the metals or pushing them through a die a single time, the researchers used cyclic extrusion–compression, a severe plastic deformation method in which the sample is repeatedly extruded and compressed through a cyclic die geometry. Each pass accumulates more strain in the material without changing its overall dimensions, allowing the scientists to build up enormous cumulative deformation, up to roughly 6.72 true strain over 16 processing cycles, all performed at room temperature. That combination of massive strain accumulation and low processing temperature is precisely what makes the technique powerful for reshaping a metal’s internal architecture.

Why does hammering a metal at room temperature make it stronger? The answer lies in the metal’s grains, the microscopic crystallites that make up its structure. Severe plastic deformation shatters these grains into progressively smaller ones, and according to the well-established Hall–Petch relationship, smaller grains mean more grain boundaries blocking the movement of dislocations, the tiny defects that carry plastic flow. More obstacles mean more strength. But the story in zinc is more complicated than in familiar structural metals like steel or aluminum. Zinc has a hexagonal close-packed crystal structure with limited independent slip systems at room temperature, which makes it prone to dynamic recrystallization, a process in which new, strain-free grains nucleate and grow even while the material is still being deformed. That means the microstructure is not simply being refined; it is being continuously destroyed and rebuilt during processing, and the final properties depend on which process wins at any given moment.

To track this microscopic tug-of-war, the team characterized their samples using electron backscatter diffraction and X-ray diffraction, techniques that map grain sizes, orientations, and crystallographic texture, the preferred alignment of grains that develops during deformation. They then correlated these structural snapshots with tensile tests performed at room temperature and a strain rate of 10 to the power of minus 3 per second, a rate relevant to how implant materials would experience loading in the body. What they found was genuinely surprising: the strength of the alloys did not rise steadily with increasing deformation, as the simple grain-refinement picture would predict. Instead, the tensile response followed a non-monotonic path, rising during the first few cycles, peaking after four cycles of processing, then dipping at intermediate strains before climbing again at the highest accumulated strains.

This strength rollercoaster, the researchers conclude, is the signature of a competition between two opposing microstructural forces. In the early stages of cyclic extrusion–compression, grain refinement dominates, fragmenting the original grains and hardening the material. But as strain accumulates, strain-induced grain coarsening takes over: dynamic recrystallization and discontinuous localized grain growth allow some grains to swell at the expense of their neighbors, softening the material and lowering its strength. At still higher strains, the balance shifts again and strength recovers. The key insight is that severe plastic deformation in these alloys is never a one-way street toward finer grains; it is a dynamic equilibrium in which refinement and coarsening operate concurrently, and the net outcome depends on how much strain has been accumulated. Understanding that equilibrium gives materials scientists a dial they can turn to select the microstructure, and therefore the properties, they want.

While strength behaved erratically, ductility told a much cleaner story. The elongation of the processed alloys improved progressively and continuously with the number of deformation cycles, so that the most heavily deformed samples were also the most stretchable. This progressive ductility gain, combined with the non-monotonic strength evolution, produced the study’s most practically important result: at intermediate deformation levels, the alloys achieved an enhanced strength–ductility balance, capturing meaningful strength gains without sacrificing the elongation that biodegradable implants need to survive handling, insertion, and early-stage loading in the body. An implant that is strong but brittle could snap during surgery or fracture under sudden loads; one that is ductile but weak cannot hold a fracture together. The sweet spot between the two is exactly where this processing route delivers.

The magnesium content turned out to be a second, independent control knob. Increasing the magnesium addition from 0.5 to 1 weight percent shifted the strength maximum to higher accumulated strains, meaning the peak arrived later in the processing sequence, and it also produced higher ductility overall. Magnesium atoms dissolved in the zinc lattice impede dislocation motion through solid-solution strengthening, but they also appear to influence the dynamic recrystallization and grain growth processes that govern the microstructure during deformation. In effect, the solute atoms slow down the coarsening side of the competition, allowing refinement to dominate over a wider strain range and preserving a finer, more deformable grain structure. For implant designers, this means alloy chemistry and deformation processing can be tuned together rather than traded against each other.

The findings also place cyclic extrusion–compression in a broader landscape of severe plastic deformation techniques that have been applied to zinc and its alloys, including high-pressure torsion, equal-channel angular pressing, and multi-pass hydrostatic extrusion. Each method imposes a different strain path, temperature, and pressure state, and each produces its own characteristic mix of grain refinement, texture development, and dynamic restoration. Previous work by some of the same authors on zinc–magnesium alloys processed by high-pressure torsion, and studies by other groups using room-temperature equal-channel angular pressing on dilute zinc–magnesium alloys, had already demonstrated that severe deformation can improve mechanical performance. What the new study adds is a systematic, cycle-by-cycle map of how properties evolve with accumulated strain in a bulk processing method that is inherently scalable, since cyclic extrusion–compression works on conventional billets rather than tiny disk-shaped samples.

That scalability matters for the clinical endgame. Biodegradable zinc implants are approaching real-world use, with recent reviews documenting rapid progress toward clinical translation of zinc-based stents, osteosynthesis devices, and bone scaffolds, and with alloy systems such as zinc–lithium–calcium and zinc–strontium already showing promising results in animal models of critical-sized bone defects. For these devices to succeed, manufacturers need processing routes that reliably produce the right combination of strength, ductility, and predictable degradation, using equipment compatible with industrial production. A room-temperature, multi-cycle deformation process that yields an optimized strength–ductility balance without exotic alloying additions or high-temperature treatments fits that requirement well, and the ability to stop processing at an intermediate cycle count gives manufacturers a simple way to hit a target property profile.

The study, funded through the Excellence Initiative–Research University programme at AGH University of Krakow, ultimately delivers a conceptual lesson that reaches beyond zinc. It demonstrates that in metals prone to dynamic recrystallization, the relationship between accumulated strain and mechanical properties is fundamentally non-monotonic, governed by the simultaneous operation of refinement and coarsening mechanisms rather than by refinement alone. For the emerging field of biodegradable metals, that insight transforms severe plastic deformation from a blunt instrument into a precision tool: by choosing the right magnesium content and the right number of processing cycles, researchers can now navigate the strength–ductility landscape of zinc–magnesium alloys deliberately, steering toward the microstructures that temporary implants demand. As the demand for implants that heal the body and then disappear continues to grow, metals that are twisted, compressed, and rebuilt at the grain level may well be the ones that hold our bones together last.

Subject of Research: Severe plastic deformation processing of biodegradable zinc–magnesium alloys for temporary implants

Article Title: Microstructural evolution and mechanical properties of Zn–Mg alloys processed by cyclic extrusion–compression

Article References: Sułkowski, B., Pałka, P., Boczkal, G., Mroczkowski, M., & Kula, A. (2026). Microstructural evolution and mechanical properties of Zn–Mg alloys processed by cyclic extrusion–compression. Journal of Materials Science, 61(43), 34293-34314. https://doi.org/10.1007/s10853-026-13817-2

Image Credits: AI Generated

DOI: 10.1007/s10853-026-13817-2

Keywords: zinc alloys, magnesium, biodegradable implants, severe plastic deformation, cyclic extrusion–compression, grain refinement, dynamic recrystallization, strength–ductility balance, microstructure, biomaterials, mechanical properties, Journal of Materials Science

The research, published in the journal Plant and Soil, was led by Xinyao Sun and Xinying Zhang of Fujian Normal University, together with Fuzhong Wu and Xiangyin Ni, working in collaboration with the Fujian Sanming Forest Ecosystem National Observation and Research Station. The team collected leaf samples from 53 subtropical tree species in China and analyzed lipid biomarkers to characterize the compounds present in each leaf. From these molecular profiles, they calculated two key quantities: lipid concentration, the total amount of lipid material per unit of leaf tissue, and lipid richness, a measure of the diversity of lipid compounds a leaf produces.

Lipids are far more than passive storage droplets. In plants, they form the structural backbone of every cellular membrane, seal the leaf surface in the waxy cuticle that controls water loss, and serve as a dense, energy-rich form of stored carbon. Because building lipids costs substantial carbon and energy, the amount and variety of lipids in a leaf effectively record how a plant has chosen to invest its photosynthetic income. That makes lipid traits a potentially integrative indicator of physiological strategy, one that captures structural protection, metabolic regulation, and carbon storage in a single biochemical signature.

The central finding of the study is a clean split between the two great phenological groups of temperate and subtropical forests. In evergreen species, which hold their leaves for multiple seasons, lipid concentrations were most strongly associated with structural traits, particularly leaf mass per area and leaf thickness. In deciduous species, which rebuild their entire canopy every year, lipid concentrations instead tracked nutrient traits, most notably the concentrations of potassium and magnesium. In other words, the same biochemical currency is governed by different economic rules depending on how long a tree expects its leaves to last.

This pattern makes intuitive biological sense when unpacked. Evergreen leaves must survive droughts, frosts, herbivores, and months of environmental punishment, so they tend to be thick, tough, and heavily armored with cuticular wax and other lipid-derived protective layers. Leaf mass per area, a cornerstone trait of the leaf economics spectrum, reflects precisely this investment in durable construction. For evergreens, then, a high lipid concentration goes hand in hand with building a leaf that is built to endure, and the lipid signal is essentially a record of structural defense.

Deciduous trees play a different game. Their leaves are short-lived, cheap to construct relative to their lifespan, and optimized for rapid photosynthesis during the growing season. For these species, lipid production appears to be tied less to armor and more to the metabolic machinery that keeps a fast-paced leaf running. Potassium is a vital regulator of plant responses to abiotic stress and a central player in enzyme activation and stomatal function, while magnesium sits at the heart of the chlorophyll molecule and is essential for membrane processes. The finding that deciduous leaf lipids align with these nutrient traits suggests that in short-lived leaves, lipids are deployed chiefly in service of active metabolism rather than long-term structural protection.

The study’s authors argue that this phenological split demonstrates that lipid-trait relationships are not universal, and that lipids may offer a more integrative indication of plant physiological investment than conventional morphological or nutrient traits alone. A measurement of leaf nitrogen or leaf mass per area tells you one dimension of a leaf’s strategy; a lipid profile, by contrast, reflects structural protection, metabolic regulation, and carbon storage simultaneously. In an era when ecosystem models increasingly need to predict not just how fast forests grow but where their carbon ends up, that integrative quality could prove valuable.

The implications extend below ground. Plant-derived lipids have been shown to play a crucial role in forest soil carbon accumulation, because lipid-rich leaf and root litter contributes compounds that can persist in soils and become stabilized within mineral-associated organic matter. If evergreen and deciduous trees differ systematically in the amount and composition of lipids they pack into their leaves, then the two forest types may also differ in the molecular quality of the organic matter they deliver to the soil. That could help explain why forests dominated by different leaf habits accumulate and stabilize soil carbon at different rates, a question of growing urgency as subtropical forests face shifting disturbance regimes and climate pressures.

The work also connects to a broader effort to enrich plant functional trait ecology with biochemical dimensions. The global leaf economics spectrum, established through worldwide measurements of traits such as photosynthetic rates, leaf lifespan, and nutrient content, has been remarkably successful at predicting everything from litter decomposition rates to ecosystem productivity. But recent studies have argued that predictions of ecosystem functioning could be improved by adding traits that capture plant chemistry more directly. Lipid concentration and lipid richness, measured here with biomarker analyses that have long been used in soil and sediment science, represent exactly such an addition: a biochemical layer of information that sits between the morphology of the leaf and the molecular fate of its carbon.

For the subtropical forests of China, where evergreen broadleaved species dominate much of the landscape and plantations of fast-growing species are widespread, the findings offer a practical lens on foliar carbon allocation. The authors conclude that leaf lipid concentration and composition are associated with conventional leaf functional traits and differ between evergreen and deciduous species, and that lipid traits therefore represent an important biochemical dimension of plant functional strategies. As carbon cycle models strive to capture the fate of photosynthesized carbon from canopy to soil, the humble fats of a leaf, long overlooked in favor of nitrogen and carbon isotopes, may turn out to be one of the most revealing ledgers a forest keeps.

Subject of Research: Leaf lipid traits and carbon allocation strategies in evergreen versus deciduous subtropical trees

Article Title: Leaf lipid traits reflect contrasting carbon allocation strategies between evergreen and deciduous trees

Article References: Sun, X., Zhang, X., Wu, F., & Ni, X. (2026). Leaf lipid traits reflect contrasting carbon allocation strategies between evergreen and deciduous trees. Plant and Soil. https://doi.org/10.1007/s11104-026-09041-1

Image Credits: AI Generated

DOI: 10.1007/s11104-026-09041-1

Keywords: leaf lipids, lipid biomarkers, evergreen trees, deciduous trees, leaf economics spectrum, leaf mass per area, carbon allocation, subtropical forests, plant functional traits, potassium, magnesium, soil carbon

The central concept in the review is bioavailability, defined as the proportion of ingested magnesium that is absorbed and utilized by the body. This is where the science becomes technically interesting, because the number printed on a supplement label reflects only the total elemental magnesium content of the compound, not how much of it will survive the journey through the gastrointestinal tract and into circulation. Magnesium oxide, one of the cheapest and most common forms on the market, delivers a high elemental load but dissolves poorly in intestinal fluids, and comparative studies have repeatedly shown that more soluble salts outperform it. In a randomized cross-over study, magnesium citrate produced higher urinary excretion and serum levels than magnesium oxide after single-dose administration, and earlier work comparing the two salts reached similar conclusions.

The review organizes supplement forms into a hierarchy of chemical classes: inorganic salts such as oxide and chloride, organic salts such as citrate, lactate, and aspartate, chelated forms in which magnesium is bound to amino acids, and advanced formulations that use encapsulation or controlled-release technology. Organic salts and chelates generally offer better solubility, gastrointestinal tolerability, and bioavailability than magnesium oxide, although the authors caution that outcomes vary with the specific formulation, the dose, the food matrix consumed alongside it, and individual physiological characteristics. In other words, there is no single universal winner; the performance of a magnesium product emerges from an interaction between chemistry and context.

Understanding how the intestine absorbs magnesium helps explain these differences. Absorption occurs along the small intestine and, to a lesser extent, the colon through two mechanistically distinct pathways. At low luminal concentrations, magnesium crosses the epithelium via saturable, transcellular channels, a process that can be regulated according to the body’s magnesium status. When luminal concentrations rise, a second, paracellular pathway allows magnesium to flow between cells down its electrochemical gradient in a non-saturable manner. This dual system has a practical consequence that many consumers miss: very large doses do not proportionally increase absorption, because the saturable pathway becomes overwhelmed and the passive pathway captures only a fraction of the remaining load. Splitting a dose or choosing a form that dissolves efficiently can therefore matter more than simply taking more milligrams.

Dietary context exerts a powerful influence on how much magnesium the gut actually takes up, and the review details both the enhancers and the saboteurs. On the positive side, fermentable fibers such as inulin, fructo-oligosaccharides, galactooligosaccharides, resistant starch, and resistant maltodextrin stimulate microbial fermentation in the colon, lowering pH and promoting mineral solubility and absorption. Human studies have shown that five weeks of short-chain fructo-oligosaccharide intake increased intestinal magnesium absorption and status in postmenopausal women, and similar benefits have been documented in adolescent girls. Proteins and medium-chain triglycerides also support absorption; medium-chain fatty acids improved calcium and magnesium uptake in patients with intestinal resections, and medium-chain triglyceride feeding enhanced mineral absorption in premature infants.

On the inhibitory side of the ledger sit phytate, oxalic acid, and certain polyphenols, all of which form poorly soluble complexes with magnesium ions in the gut lumen. Phytic acid added to white wheat bread significantly reduced fractional apparent magnesium absorption in human subjects, and spinach, a vegetable rich in both magnesium and oxalate, delivered less absorbable magnesium than kale, which has a low oxalate content despite comparable mineral content on paper. These findings carry a counterintuitive message: a food can be chemically rich in magnesium yet nutritionally poor as a source of it. Food processing can shift the balance, however, because sourdough fermentation activates endogenous phytase enzymes and a moderate pH decrease is sufficient to degrade much of the phytate in whole wheat flour, restoring the bioavailability of the grain’s minerals.

The review also highlights how formulation technology is reshaping the supplement landscape. Microencapsulated magnesium products, in which the mineral is wrapped in protective coatings, have shown improved absorption and fewer gastrointestinal side effects in comparative clinical studies. Sucrosomial magnesium, a formulation in which the mineral is carried inside phospholipid vesicles, demonstrated favorable bioavailability in both ex vivo work and a double-blinded cross-over study in healthy subjects. Extended-release matrices offer a different strategy: a magnesium lactate dihydrate extended-release caplet showed measurable absolute bioavailability in healthy volunteers, with the slow release designed to avoid saturating the intestinal transport pathways. These advanced systems reflect a growing recognition that the delivery vehicle is as important as the salt itself.

Measuring bioavailability remains a methodological challenge, and the review surveys the tools researchers use to compare forms. Stable isotope techniques allow true fractional absorption to be tracked from a labeled dose, while urinary excretion after single doses or in magnesium-saturated subjects provides a practical proxy. Serum and circulating ionized magnesium, intracellular magnesium in leukocytes measured by X-ray dispersion analysis, and in vitro models such as Caco-2 intestinal barrier cell cultures each add complementary evidence, though animal studies, including rat work comparing ten organic and inorganic magnesium salts, sometimes show smaller differences between forms than human trials, particularly when diets are high in phytic acid. The authors argue that supplementation should be assessed beyond elemental content alone, considering absorption, retention, and ultimately tissue utilization.

For the growing population of consumers reaching for magnesium to support sleep, muscle recovery, or cardiovascular health, the practical takeaway is nuanced. The form matters, with citrate, organic salts, and chelates generally outperforming oxide; the dose and timing matter, because absorption efficiency declines as dose rises; and the meal matters, because phytate-rich and oxalate-rich foods can bind magnesium while fermentable fibers, adequate protein, and medium-chain triglycerides can enhance its uptake. Individual factors, including age-related changes in gut function and the presence of intestinal disease or resection, further modulate how much of any given dose the body retains. As the review concludes, evaluating a magnesium supplement requires looking past the label’s elemental magnesium number to the chemistry of the salt, the sophistication of the formulation, and the dietary environment in which it is taken, a framing that may finally bring rigor to one of the supplement industry’s most crowded categories.

Subject of Research: Magnesium bioavailability, intestinal absorption mechanisms, and comparative performance of dietary supplement forms

Article Title: Advances in magnesium bioavailability: dietary factors, absorption mechanisms, and comparative performance of supplement forms

Article References: Gultekin, S., & Tomas, M. (2026). Advances in magnesium bioavailability: dietary factors, absorption mechanisms, and comparative performance of supplement forms. Food Science and Biotechnology. https://doi.org/10.1007/s10068-026-02319-1

Image Credits: AI Generated

DOI: 10.1007/s10068-026-02319-1

Keywords: magnesium, bioavailability, intestinal absorption, dietary supplements, magnesium citrate, magnesium oxide, phytate, oxalate, prebiotics, microencapsulation, chelated minerals, nutritional deficiency

The enzyme in question is RNASET2, a ribonuclease best known for its role in antimicrobial defense. It chops up RNA derived from pathogens into small fragments that are subsequently detected by Toll-like receptors 7 and 8, sensors that help ignite innate immune responses. The clinical importance of this protein is underscored by a rare human condition: children born without functional RNASET2 develop cystic leukoencephalopathy, a brain disorder accompanied by elevated inflammatory markers in the cerebrospinal fluid and peripheral blood. Mice engineered to lack RNASET2 show a similar picture, with heightened expression of interferon-stimulated genes and neuroinflammation. All of this suggested that RNASET2 acts as a brake on innate immunity.

That brake, the Xiamen team reasoned, might be exactly what cancer cells exploit. Tumors routinely dampen innate immune signaling within themselves as a way of escaping immune surveillance, and any machinery that clears away danger signals could serve that purpose. The researchers therefore set out to determine whether RNASET2 contributes to this immune evasion, and whether releasing the brake could restore the tumor’s visibility to the immune system.

The danger signal RNASET2 clears is double-stranded RNA arising from the cell’s own genome. Mitochondria, the energy-producing organelles descended from ancient bacteria, continually transcribe their compact genomes, and the resulting mitochondrial double-stranded RNA can spill into the surrounding cytoplasm. Work over the past decade has established that this mitochondrial RNA is a potent trigger of innate immune pathways, and that cells must actively manage it to avoid chronic inflammation. RNASET2, the new study shows, is one of the managers: it degrades mitochondrial double-stranded RNA before it can accumulate and provoke a response.

The most striking twist in the study is chemical. RNASET2’s RNA-destroying activity is sensitive to magnesium, the abundant biological cation that sits at the heart of many enzymatic reactions. The researchers found that magnesium modulates the enzyme’s ability to clear double-stranded RNA, and that enhancing magnesium effectively inhibits RNASET2 function in this context. When RNASET2 is inhibited, mitochondrial double-stranded RNA builds up inside tumor cells, and that accumulation is not silent. The accumulating RNA trips innate immune sensors, driving the production of interferons and other inflammatory mediators that convert an immunologically cold tumor into an inflamed one.

That inflammatory conversion has direct consequences for therapy. Checkpoint inhibitors such as antibodies targeting PD-1 and PD-L1 work by releasing T cells from inhibition, but they depend on the tumor already being recognized as foreign. Tumors with high baseline innate immune signaling, often described as inflamed or hot tumors, respond far better than cold tumors that present no danger signals for T cells to act on. By forcing the accumulation of mitochondrial double-stranded RNA, RNASET2 inhibition manufactures exactly the inflammatory context that checkpoint blockade needs, and the study demonstrates that combining the two approaches boosts antitumor immunity in preclinical models.

The findings also reframe a familiar nutrient in a new light. Magnesium has long been appreciated as essential for T cell function; earlier work published in Cell in 2022 showed that magnesium is required for the proper function of cytotoxic T cells and that low magnesium environments impair their ability to kill infected or malignant cells. The new study adds a second, complementary mechanism: magnesium also shapes the innate immune landscape of the tumor itself by regulating an RNA clearance enzyme. A single ion thus influences both the effector arm of the immune response and the alarm signals that summon it, a convergence that may help explain why magnesium status correlates with cancer outcomes in epidemiological studies.

For the researchers, the path from basic enzymology to therapeutic strategy ran through a paradox. RNASET2 is, on balance, an anti-inflammatory protein, and one might expect that removing it would simply cause indiscriminate inflammation with little therapeutic benefit. Instead, the study shows that the inflammation generated by stalled RNA clearance is precisely targeted at the tumor, because it is the tumor’s own mitochondrial RNA that accumulates. This makes the intervention conceptually similar to other strategies that deliberately unleash self-derived nucleic acid sensing, such as inhibitors of TREX1 or STING agonists, but with a distinct molecular entry point and a simple dietary or pharmacological lever in the form of magnesium.

Considerable work remains before the approach could reach patients. The study is grounded in mouse models and mechanistic cell biology, and the therapeutic window will need careful definition: RNASET2 deficiency in humans causes a serious neuroinflammatory disease, so any clinical strategy must elevate RNA accumulation within tumors without reproducing systemic pathology. It is also not yet clear which tumor types, which dosing regimens of magnesium or RNASET2 inhibitors, and which combinations with existing immunotherapies would be optimal. The authors declare no competing interests, and the work was supported by the National Natural Science Foundation of China and related national programs, reflecting a sustained public investment in innate immunity research.

Even so, the study offers a memorable conceptual advance: the immune system’s alarm bells are not only rung and heard but actively muffled, and the muffling machinery can be switched off. If RNASET2 inhibition or magnesium-based approaches can be translated safely, a routine mineral could become an unlikely partner for the most sophisticated cancer drugs on the market, turning cold tumors hot by simply refusing to let them take out the trash.

Subject of Research: RNASET2-mediated clearance of mitochondrial double-stranded RNA and its inhibition to enhance cancer immunotherapy

Article Title: Inhibition of a magnesium-sensitive double-stranded RNA clearance machinery boosts cancer immunotherapy

Article References: Zhang, Z., Zhang, L., Luo, H., Huo, Y., Sun, B., Shi, J., Wu, S., Wang, P., & Wang, G. (2026). Inhibition of a magnesium-sensitive double-stranded RNA clearance machinery boosts cancer immunotherapy. Cell Research. https://doi.org/10.1038/s41422-026-01301-0

Image Credits: AI Generated

DOI: 10.1038/s41422-026-01301-0

Keywords: RNASET2, mitochondrial double-stranded RNA, cancer immunotherapy, innate immunity, magnesium, tumor immune evasion, interferon signaling, Toll-like receptors, checkpoint inhibitors, ribonuclease, tumor microenvironment, Cell Research

The case is striking not only because of the dramatic recovery but also because of the therapeutic history that preceded it. The patient had been treated with a proton pump inhibitor, a class of acid-suppressing drugs used by millions of people worldwide for reflux and ulcer disease, as well as with metformin, the first-line medication for type 2 diabetes. Both drugs are increasingly recognized as causes of magnesium depletion. Proton pump inhibitors interfere with intestinal magnesium absorption, while metformin has been linked to urinary magnesium losses in patients with diabetes. The Belgian authors note that their patient had also experienced unexplained transient neurological deficits in the past, episodes that now appear, in retrospect, to have been heralds of the same underlying electrolyte disturbance.

Magnesium is the fourth most abundant cation in the body and the second most abundant inside cells, and its physiological reach is enormous. It serves as a cofactor for hundreds of enzymatic reactions, stabilizes the electrical gradients of excitable membranes, regulates calcium channels, and modulates the release of neurotransmitters at both central and peripheral synapses. Because roughly two thirds of body magnesium is stored in bone and only a tiny fraction circulates in the plasma, the serum level is an imperfect window into total body stores. This biochemical reality helps explain why hypomagnesemia is frequently overlooked: clinicians may assume that a normal-looking electrolyte panel excludes deficiency, or simply never order the measurement at all during the chaotic early minutes of a suspected stroke.

The neurological consequences of magnesium depletion are well documented in other contexts. Low magnesium lowers the seizure threshold, produces tremor, muscle cramps, and tetany, and can cause characteristic eye-movement abnormalities and ataxia. Severe cases have even produced reversible cerebellar syndrome with brain imaging showing swelling of the cerebellum, a phenomenon described in several case reports over the past decade. What has been far rarer in the literature is the attribution of focal deficits, weakness or speech disturbance confined to one side of the body in a pattern that strongly suggests a localized brain lesion, to magnesium deficiency alone. The Belgian team argues that this rarity is at least partly an artifact of under-testing rather than a true biological rarity.

The mechanisms by which magnesium depletion could produce focal symptoms are biologically plausible. Experimental work on cerebral penetrating arterioles has shown that magnesium promotes vasodilation in these small vessels, so its absence may impair the fine regulation of blood flow in deep brain regions. Magnesium also acts as a natural antagonist of the NMDA receptor, damping excitotoxic cascades that amplify injury during ischemia, and clinical studies in patients with aneurysmal subarachnoid hemorrhage have explored magnesium infusions as a protective agent during episodes of critical perfusion. In a deficient state, the loss of these protective functions could render vulnerable brain circuits transiently dysfunctional, producing deficits that mimic vascular occlusion but reverse when the electrolyte balance is restored.

Stroke mimics are far from a marginal concern in emergency neurology. Large registries of patients referred to stroke services have found that a substantial proportion of code-stroke activations ultimately receive a non-ischemic diagnosis, ranging from seizures and migraines to metabolic derangements and functional disorders. Distinguishing true stroke from mimic is one of the hardest tasks in acute medicine, because the cost of missing a real infarct is measured in dead brain tissue, while the cost of treating a mimic with thrombolytics includes potentially catastrophic bleeding. Imaging tools such as CT perfusion have improved this discrimination, but they depend on recognizing which metabolic conditions can distort the pictures they produce. A severe electrolyte abnormality that resolves with repletion belongs firmly on that list.

The literature review accompanying the Belgian case assembles the scattered evidence that severe hypomagnesemia can indeed present as an acute stroke. Earlier reports have described patients in emergency settings and in rehabilitation units whose hemiparesis and aphasia cleared after magnesium replacement, and a 2025 review in Neurological Sciences explicitly asked whether hypomagnesemia is a rare but overlooked stroke mimic. The pattern across these reports is consistent: the patients often carry risk factors for magnesium wasting, such as proton pump inhibitor use, diuretics, alcohol use, diabetes, or diarrhea, and their deficits improve as the serum level normalizes, a trajectory that would be unusual for a completed infarct. The authors of the new report emphasize that despite this documentation, magnesium levels are rarely measured during the acute phase of a suspected stroke.

Why does this gap persist? Part of the answer lies in the historical organization of emergency testing. A classic study from 1990 found that when serum magnesium was measured routinely rather than only when specifically requested, previously unrecognized hypomagnesemia was detected at a meaningful rate, suggesting that clinicians systematically underestimate its prevalence. Magnesium also interacts closely with potassium homeostasis, so refractory hypokalemia is a well-known clue to coexisting magnesium depletion, yet this teaching point competes with dozens of others in crowded emergency protocols. In the hyperacute stroke pathway, where every additional test is weighed against the clock, magnesium has simply never earned a place on the mandatory panel. The Belgian authors argue that the case they present, together with the accumulating literature, makes a compelling case for changing that practice.

The clinical implications are considerable. For patients on proton pump inhibitors and metformin, the combination seen in this case, the possibility of drug-induced magnesium wasting deserves explicit attention whenever neurological symptoms appear, particularly if the deficits fluctuate or if vascular imaging fails to show an occlusion. For stroke teams, the report suggests that a serum magnesium level, a cheap and rapid assay available in virtually every hospital laboratory, could be added to the initial workup of suspected stroke without meaningfully delaying treatment. Identifying a reversible metabolic mimic before administering thrombolytic drugs would spare patients an unnecessary bleeding risk, and correcting the deficiency could resolve deficits that would otherwise trigger days of admission, monitoring, and secondary stroke workup aimed at a vascular cause that does not exist.

The Belgian case report, approved by the ethics committee of the Hopital Civil Marie Curie in Charleroi and published with the patient’s informed consent, is unlikely to overturn stroke care on its own. But it adds a vivid data point to a quiet shift in neurological thinking: that the electrolyte milieu of the brain is not a background variable but an active determinant of focal function. As the authors and their predecessors in the literature suggest, some of the deficits long assumed to be vascular may instead be the nervous system’s distress signal when a critical mineral runs out. For a condition whose treatment is as simple as magnesium repletion, overlooking it is a luxury that emergency medicine can no longer afford.

Subject of Research: Severe hypomagnesemia as a reversible stroke mimic causing focal neurological deficits

Article Title: Stroke mimic caused by severe hypomagnesemia: a case report and literature review

Article References: Vidal Bankier, D., Renard, F., & Manto, M. (2026). Stroke mimic caused by severe hypomagnesemia: a case report and literature review. Journal of Neurology, 273(10), Article 632. https://doi.org/10.1007/s00415-026-14155-8

Image Credits: AI Generated

DOI: 10.1007/s00415-026-14155-8

Keywords: hypomagnesemia, stroke mimic, magnesium, neurology, proton pump inhibitors, metformin, aphasia, hemiparesis, emergency medicine, electrolytes, case report, Journal of Neurology